Treg cells constitutively express Glucocorticoid-induced tumor necrosis factor related protein (GITR); Anti-GITR agonistic antibody therapy has gained attention as a therapeutic target in GBM due to the success of the therapy in other cancer models, such as bladder cancers in mice (1). The gene discussed is TNFRSF18; the disease is urinary bladder carcinoma.